Glenmark Pharmaceuticals Presenting New Data from Respiratory Portfolio at the ACAAI Annual Scientific Meeting 2017

Mahwah, NJ; October 23, 2017 – Glenmark Pharmaceuticals, a global pharmaceutical company, today announced that the company is presenting new data at the upcoming American College of Allergy, Asthma and Immunology Annual Scientific Meeting (ACAAI 2017) in Boston, Massachusetts. The Glenmark presentations include results of clinical trials for GSP 301, an investigational fixed-dose combination treatment for seasonal allergic rhinitis (SAR) and one of the company’s leading pipeline candidates.

“Glenmark is growing into a diversified pharmaceutical company with a pipeline of investigational new drugs, and the data being presented at ACAAI 2017 is an important step in that growth,” said Fred Grossman, President and Chief Medical Officer at Glenmark Pharmaceuticals. “These data will form the basis of a New Drug Application, and if approved, GSP 301 will provide another important combination therapy option for the treatment of SAR.”   The scheduled times (noted in Eastern Time) of the presentations at the Hynes Convention Center are as follows:

• Efficacy and Safety of Once-daily and Twice-daily Olopatadine/Mometasone Nasal Spray Treatment in Seasonal Allergic Rhinitis
  • Presenter: Charles P. Andrews
  • Poster #: P433
  • Friday, October 27 4:40 PM ET
• Efficacy and Safety of Olopatadine/Mometasone Combination Nasal Spray for the Treatment of Seasonal Allergic Rhinitis
  • Presenter: Sudeesh K. Tantry
  • Poster #: P434
  • Friday, October 27 4:50 PM ET
• Olopatadine/Mometasone Combination Nasal Spray Improves Seasonal Allergic Rhinitis Symptoms in a Ragweed Environmental Exposure Chamber
  • Presenter: Ann Marie Salapatek
  • Poster #: P435
  • Friday, October 27 5:00 PM ET

About Seasonal Allergic Rhinitis

Twenty million adults in the United Sates are affected by seasonal allergic rhinitis, also called hay fever, every year.¹ It is the primary diagnosis in over 11 million doctor’s visits and is estimated to affect more than seven percent of adults aged 18 and over in the United States.^2,3 As of August 2017, more than 50 million prescription nasal sprays were dispensed for allergic rhinitis annually in the U.S., amounting to $1 billion in sales.⁴

About Glenmark’s Respiratory Pipeline

Glenmark’s respiratory pipeline is specifically aimed at addressing the global public health burden of allergic rhinitis, asthma, and chronic obstructive pulmonary disease (COPD), and includes five investigational treatments across the disease spectrum and devices. This includes GSP 301, a combination steroid plus antihistamine nasal spray being investigated for the treatment of allergic rhinitis which has completed three Phase 3 trials and is preparing for a New Drug Application submission; GSP 304, currently in Phase 2 trials, which is a long acting muscarinic receptor agonist being investigated as a nebulized treatment for COPD; GBR 310, a proposed biosimilar candidate of omalizumab for the treatment of allergic asthma and chronic idiopathic urticaria; and GRC 39815, which is pre-clinically being investigated for the treatment of COPD.

About Glenmark Pharmaceuticals

Glenmark Pharmaceuticals Ltd. (GPL) is a global innovative pharmaceutical company with operations in more than 50 countries. Glenmark has a diverse pipeline with several compounds in various stages of clinical development, primarily focused in the areas of oncology, respiratory disease, and dermatology. Glenmark has improved the lives of millions of patients by offering safe, affordable medications for nearly 40 years. For more information, visit www.glenmarkpharma.com.

For further information, please contact:
An Phan
(201) 778-3272

Ramkumar Uppara and Shibani Shah
+91-22-401-89984 x348
corpcomm@glenmarkpharma.com

¹ Centers for Disease Control and Prevention. Allergies and Hay Fever.
² National Ambulatory Medical Care Survey: 2010 Summary Tables, Table 13.
³ Summary Health Statistics for U.S. Adults: National Health Interview Survey, 2010.
⁴ IMS Health National Sales Perspectives: Retail, Non-Retail, and Mail Order, August 2017

Glenmark Pharmaceuticals Presenting New Data from Respiratory Portfolio at the ACAAI Annual Scientific Meeting 2017

Mahwah, NJ; October 23, 2017 – Glenmark Pharmaceuticals, a global pharmaceutical company, today announced that the company is presenting new data at the upcoming American College of Allergy, Asthma and Immunology Annual Scientific Meeting (ACAAI 2017) in Boston, Massachusetts. The Glenmark presentations include results of clinical trials for GSP 301, an investigational fixed-dose combination treatment for seasonal allergic rhinitis (SAR) and one of the company’s leading pipeline candidates.

“Glenmark is growing into a diversified pharmaceutical company with a pipeline of investigational new drugs, and the data being presented at ACAAI 2017 is an important step in that growth,” said Fred Grossman, President and Chief Medical Officer at Glenmark Pharmaceuticals. “These data will form the basis of a New Drug Application, and if approved, GSP 301 will provide another important combination therapy option for the treatment of SAR.”   The scheduled times (noted in Eastern Time) of the presentations at the Hynes Convention Center are as follows:

• Efficacy and Safety of Once-daily and Twice-daily Olopatadine/Mometasone Nasal Spray Treatment in Seasonal Allergic Rhinitis
  • Presenter: Charles P. Andrews
  • Poster #: P433
  • Friday, October 27 4:40 PM ET
• Efficacy and Safety of Olopatadine/Mometasone Combination Nasal Spray for the Treatment of Seasonal Allergic Rhinitis
  • Presenter: Sudeesh K. Tantry
  • Poster #: P434
  • Friday, October 27 4:50 PM ET
• Olopatadine/Mometasone Combination Nasal Spray Improves Seasonal Allergic Rhinitis Symptoms in a Ragweed Environmental Exposure Chamber
  • Presenter: Ann Marie Salapatek
  • Poster #: P435
  • Friday, October 27 5:00 PM ET

About Seasonal Allergic Rhinitis

Twenty million adults in the United Sates are affected by seasonal allergic rhinitis, also called hay fever, every year.¹ It is the primary diagnosis in over 11 million doctor’s visits and is estimated to affect more than seven percent of adults aged 18 and over in the United States.^2,3 As of August 2017, more than 50 million prescription nasal sprays were dispensed for allergic rhinitis annually in the U.S., amounting to $1 billion in sales.⁴

About Glenmark’s Respiratory Pipeline

Glenmark’s respiratory pipeline is specifically aimed at addressing the global public health burden of allergic rhinitis, asthma, and chronic obstructive pulmonary disease (COPD), and includes five investigational treatments across the disease spectrum and devices. This includes GSP 301, a combination steroid plus antihistamine nasal spray being investigated for the treatment of allergic rhinitis which has completed three Phase 3 trials and is preparing for a New Drug Application submission; GSP 304, currently in Phase 2 trials, which is a long acting muscarinic receptor agonist being investigated as a nebulized treatment for COPD; GBR 310, a proposed biosimilar candidate of omalizumab for the treatment of allergic asthma and chronic idiopathic urticaria; and GRC 39815, which is pre-clinically being investigated for the treatment of COPD.

About Glenmark Pharmaceuticals

Glenmark Pharmaceuticals Ltd. (GPL) is a global innovative pharmaceutical company with operations in more than 50 countries. Glenmark has a diverse pipeline with several compounds in various stages of clinical development, primarily focused in the areas of oncology, respiratory disease, and dermatology. Glenmark has improved the lives of millions of patients by offering safe, affordable medications for nearly 40 years. For more information, visit www.glenmarkpharma.com.

For further information, please contact:
An Phan
(201) 778-3272

Ramkumar Uppara and Shibani Shah
+91-22-401-89984 x348
corpcomm@glenmarkpharma.com

¹ Centers for Disease Control and Prevention. Allergies and Hay Fever.
² National Ambulatory Medical Care Survey: 2010 Summary Tables, Table 13.
³ Summary Health Statistics for U.S. Adults: National Health Interview Survey, 2010.
⁴ IMS Health National Sales Perspectives: Retail, Non-Retail, and Mail Order, August 2017